Screening breast, ovarian cancer gene mutations other than BRCA1/2 impact management
the ONA take:
Multigene testing for hereditary breast and/or ovarian cancer that tests for more gene mutations than BRCA1/2 is more likely to inform clinical decision-making than testing for BRCA1/2 alone, according to a new study published online ahead of print in JAMA Oncology.
"The traditional approach has been to test most women with suspected hereditary risk for breast and/or ovarian cancer for BRCA1/2 alone," senior author Leif Ellisen, MD, PhD, program director for Breast Medical Oncology at the MGH Cancer Center said.
Of 1,046 study participants, 40 BRCA1/2-negative patients harbored deleterious mutations. The most common mutations were in CHECK2, ATM, PALB2, and Lynch syndrome genes. Researchers found that for the majority those and an additional 23 mutation-positive patients their clinics, additional disease-specific screening and/or prevention measures other than those based on personal and family history alone would be considered.
"Our study shows that, even under current practice guidelines, finding mutations in these other genes is likely to change the clinical management recommendations both for patients and for family members who also carry the associated mutations," explains Dr. Ellisen.
Multigene testing for hereditary breast and/or ovarian cancer that tests is more likely to inform clinical decision-making than testing for BRCA1/2 alone.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- MRD Negativity Associated With Prolonged Survival in Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|